单克隆抗体治疗,疫苗接种和急性COVID-19后的长期症状缓解之间的关联
Samantha C Roberts1, Sarah E Jolley2, Laurel E Beaty1
1Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA.
Journal of medical virology
|March 22, 2024
概括
接种COVID-19疫苗,但不是单克隆抗体 (mAb) 治疗,缩短了症状恢复时间. 接种疫苗和mAb治疗都降低了COVID-19患者28天住院的风险.
科学领域:
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
- 公共卫生 公共卫生
背景情况:
- 由于缺乏有效的治疗方法,COVID-19 (PASC) 后急性后续症是一个重大挑战.
- 了解影响症状恢复和住院的因素对于管理COVID-19流行病至关重要.
- 单克隆抗体 (mAb) 治疗和COVID-19疫苗接种是关键干预措施,但它们对PASC症状解决的影响需要进一步评估.
研究的目的:
- 评估单克隆抗体 (mAb) 治疗或COVID-19疫苗接种与对SARS-CoV-2阳性测试成人的症状恢复之间的关联.
- 评估这些干预措施对症状缓解的时间和28天住院的风险的影响.
主要方法:
- 从2021年4月到2022年1月,在一个多医院卫生系统中进行了一项基于调查的纵向队列研究.
- 包括1612名成年参与者 (≥18岁) 具有阳性SARS-CoV-2测试.
- 主要暴露包括mAb治疗和COVID-19疫苗接种 (≥2剂量);主要结果是症状消失的时间;次要结果是28天住院治疗.
主要成果:
- 在接受mAb治疗和未接受治疗的患者 (aHR:0.90) 之间,症状消失的时间与症状消失的时间相似.
- 与未接种疫苗的患者相比,接受≥2剂COVID-19疫苗的患者的症状缓解时间较短 (aHR: 1.56).
- 两种mAb疗法 (aOR:0.31) 和≥2剂疫苗 (aOR:0.33) 都与28天住院的风险明显降低相关.
结论:
- 接种COVID-19疫苗与SARS-CoV-2感染后的症状加速消失有关.
- 无论是mAb疗法还是COVID-19疫苗接种,都表明短期住院的风险显著降低.
- 进一步的研究可能会探索优化PASC的治疗策略和预防严重后果.
更多相关视频
15:57Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle
Published on: July 11, 2015
12.2K
09:57Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
11.9K
相关概念视频
Vaccinations
44.5K
Overview
44.5K
Immunological Memory
605
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
605
Tumor Immunotherapy
523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Cross-reactivity
31.1K
Overview
31.1K
Cancer Vaccines
363
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
363
Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K
